Alzheon, Inc., a clinical-stage biopharmaceutical company focused on brain health, memory and aging, today announced that it will present at the Cowen & Company 34th Annual Health Care Conference at 12:00 noon ET on Monday, March 3, 2014, at the Boston Marriott Copley Place in Boston, MA. Martin Tolar, MD, PhD, Founder, President and CEO of Alzheon, will present at the conference to provide an overview of Alzheon’s drug development pipeline in Alzheimer’s disease, including ALZ-801, the company’s lead clinical candidate starting confirmatory pivotal Phase 2/3 study in early 2015 in Alzheimer’s disease patients positive for e4 allele of the apolipoprotein E. The presentation will be available on Alzheon’s website www.alzheon.com, under Press Releases.
Help employers find you! Check out all the jobs and post your resume.
